JP2013545759A - 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 - Google Patents
低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 Download PDFInfo
- Publication number
- JP2013545759A JP2013545759A JP2013540063A JP2013540063A JP2013545759A JP 2013545759 A JP2013545759 A JP 2013545759A JP 2013540063 A JP2013540063 A JP 2013540063A JP 2013540063 A JP2013540063 A JP 2013540063A JP 2013545759 A JP2013545759 A JP 2013545759A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ldh
- tumor
- hypoxia
- ldh5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 397
- 230000007954 hypoxia Effects 0.000 title claims abstract description 256
- 238000011282 treatment Methods 0.000 title claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 447
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims abstract description 320
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims abstract description 320
- 201000011510 cancer Diseases 0.000 claims abstract description 194
- 238000000034 method Methods 0.000 claims abstract description 117
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims description 152
- 230000000694 effects Effects 0.000 claims description 138
- 230000001146 hypoxic effect Effects 0.000 claims description 129
- 239000000523 sample Substances 0.000 claims description 129
- 230000014509 gene expression Effects 0.000 claims description 127
- 108010029485 Protein Isoforms Proteins 0.000 claims description 121
- 102000001708 Protein Isoforms Human genes 0.000 claims description 121
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 84
- 210000001519 tissue Anatomy 0.000 claims description 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 238000001514 detection method Methods 0.000 claims description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 56
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 56
- 229920001184 polypeptide Polymers 0.000 claims description 56
- 102100031357 L-lactate dehydrogenase C chain Human genes 0.000 claims description 54
- 101150050566 LDHC gene Proteins 0.000 claims description 54
- 101150035055 ldh3 gene Proteins 0.000 claims description 54
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 claims description 51
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 claims description 48
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims description 48
- 206010033128 Ovarian cancer Diseases 0.000 claims description 36
- 201000001441 melanoma Diseases 0.000 claims description 36
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 34
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 34
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims description 32
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 101001051207 Homo sapiens L-lactate dehydrogenase B chain Proteins 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 28
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims description 27
- 206010039491 Sarcoma Diseases 0.000 claims description 27
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 27
- -1 LDH4 Proteins 0.000 claims description 26
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 25
- 208000037819 metastatic cancer Diseases 0.000 claims description 25
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 25
- 108091006296 SLC2A1 Proteins 0.000 claims description 24
- 108091006299 SLC2A2 Proteins 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 22
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 21
- 201000005202 lung cancer Diseases 0.000 claims description 21
- 208000020816 lung neoplasm Diseases 0.000 claims description 21
- 238000011269 treatment regimen Methods 0.000 claims description 21
- 206010009944 Colon cancer Diseases 0.000 claims description 20
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 20
- 230000008859 change Effects 0.000 claims description 20
- 208000029742 colonic neoplasm Diseases 0.000 claims description 20
- 208000021039 metastatic melanoma Diseases 0.000 claims description 20
- 230000008901 benefit Effects 0.000 claims description 19
- 208000005017 glioblastoma Diseases 0.000 claims description 19
- 201000007270 liver cancer Diseases 0.000 claims description 19
- 208000014018 liver neoplasm Diseases 0.000 claims description 19
- 210000002751 lymph Anatomy 0.000 claims description 19
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 19
- 230000000306 recurrent effect Effects 0.000 claims description 19
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 19
- 210000002700 urine Anatomy 0.000 claims description 19
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 230000017531 blood circulation Effects 0.000 claims description 18
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims description 17
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims description 17
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 17
- 108091008605 VEGF receptors Proteins 0.000 claims description 17
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- 230000002085 persistent effect Effects 0.000 claims description 17
- 229950010456 pimonidazole Drugs 0.000 claims description 17
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 claims description 16
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 16
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 16
- 206010018338 Glioma Diseases 0.000 claims description 16
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 16
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 15
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 claims description 15
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 15
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 15
- 208000032839 leukemia Diseases 0.000 claims description 15
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 101150095787 ldh2 gene Proteins 0.000 claims description 14
- 101150100271 ldhb gene Proteins 0.000 claims description 14
- 230000001394 metastastic effect Effects 0.000 claims description 14
- 210000000988 bone and bone Anatomy 0.000 claims description 13
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 13
- 210000003567 ascitic fluid Anatomy 0.000 claims description 12
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 206010036790 Productive cough Diseases 0.000 claims description 11
- 206010038389 Renal cancer Diseases 0.000 claims description 11
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 11
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 11
- 210000000416 exudates and transudate Anatomy 0.000 claims description 11
- 201000010982 kidney cancer Diseases 0.000 claims description 11
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 11
- 210000003802 sputum Anatomy 0.000 claims description 11
- 208000024794 sputum Diseases 0.000 claims description 11
- 201000002510 thyroid cancer Diseases 0.000 claims description 11
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 10
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 10
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 10
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 10
- 206010057644 Testis cancer Diseases 0.000 claims description 10
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 10
- 206010024627 liposarcoma Diseases 0.000 claims description 10
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 201000003120 testicular cancer Diseases 0.000 claims description 10
- 206010046766 uterine cancer Diseases 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims description 9
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 9
- 208000032612 Glial tumor Diseases 0.000 claims description 9
- 208000034578 Multiple myelomas Diseases 0.000 claims description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 9
- 210000003608 fece Anatomy 0.000 claims description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 9
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 206010004593 Bile duct cancer Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 8
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 8
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 8
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 8
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 8
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 8
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 8
- 208000005890 Neuroma Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 8
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 8
- 201000000582 Retinoblastoma Diseases 0.000 claims description 8
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 8
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 8
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 8
- 201000009036 biliary tract cancer Diseases 0.000 claims description 8
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 8
- 201000007455 central nervous system cancer Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 208000021622 familial nonmedullary thyroid carcinoma Diseases 0.000 claims description 8
- 201000010175 gallbladder cancer Diseases 0.000 claims description 8
- 210000004392 genitalia Anatomy 0.000 claims description 8
- 201000011066 hemangioma Diseases 0.000 claims description 8
- 230000009033 hematopoietic malignancy Effects 0.000 claims description 8
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 8
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 8
- 201000005831 male reproductive organ cancer Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 206010027191 meningioma Diseases 0.000 claims description 8
- 201000003731 mucosal melanoma Diseases 0.000 claims description 8
- 230000001537 neural effect Effects 0.000 claims description 8
- 208000007538 neurilemmoma Diseases 0.000 claims description 8
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 8
- 201000006958 oropharynx cancer Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 208000028591 pheochromocytoma Diseases 0.000 claims description 8
- 206010038038 rectal cancer Diseases 0.000 claims description 8
- 201000001275 rectum cancer Diseases 0.000 claims description 8
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 8
- 206010039667 schwannoma Diseases 0.000 claims description 8
- 210000001625 seminal vesicle Anatomy 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 201000002314 small intestine cancer Diseases 0.000 claims description 8
- 210000004872 soft tissue Anatomy 0.000 claims description 8
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 201000010653 vesiculitis Diseases 0.000 claims description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 7
- 208000021309 Germ cell tumor Diseases 0.000 claims description 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 7
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims description 7
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 7
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 7
- 208000024519 eye neoplasm Diseases 0.000 claims description 7
- 208000029824 high grade glioma Diseases 0.000 claims description 7
- 230000036210 malignancy Effects 0.000 claims description 7
- 201000011614 malignant glioma Diseases 0.000 claims description 7
- 208000022006 malignant tumor of meninges Diseases 0.000 claims description 7
- 201000008106 ocular cancer Diseases 0.000 claims description 7
- 208000007312 paraganglioma Diseases 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 230000000750 progressive effect Effects 0.000 claims description 7
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims description 6
- 208000002409 gliosarcoma Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000002511 pituitary cancer Diseases 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 11
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 5
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 5
- 210000004500 stellate cell Anatomy 0.000 claims 5
- 239000003550 marker Substances 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 39
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 35
- 239000001301 oxygen Substances 0.000 description 35
- 229910052760 oxygen Inorganic materials 0.000 description 35
- 201000010099 disease Diseases 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 28
- 238000003556 assay Methods 0.000 description 28
- 230000004083 survival effect Effects 0.000 description 28
- 230000037361 pathway Effects 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 21
- 230000004044 response Effects 0.000 description 18
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 17
- 239000013068 control sample Substances 0.000 description 17
- 238000003384 imaging method Methods 0.000 description 17
- 229940076788 pyruvate Drugs 0.000 description 17
- 238000005259 measurement Methods 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 229930012538 Paclitaxel Natural products 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 229960001592 paclitaxel Drugs 0.000 description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 13
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 12
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 230000007717 exclusion Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 10
- 230000009401 metastasis Effects 0.000 description 10
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 9
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 238000007619 statistical method Methods 0.000 description 9
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 208000023589 ischemic disease Diseases 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 6
- 206010061309 Neoplasm progression Diseases 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000012151 immunohistochemical method Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 6
- 229940038773 trisodium citrate Drugs 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 230000005751 tumor progression Effects 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000001952 enzyme assay Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 206010070308 Refractory cancer Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000012296 in situ hybridization assay Methods 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000013077 scoring method Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- BKJIXTWSNXCKJH-UHFFFAOYSA-N elesclomol Chemical compound C=1C=CC=CC=1C(=S)N(C)NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1 BKJIXTWSNXCKJH-UHFFFAOYSA-N 0.000 description 3
- 201000011523 endocrine gland cancer Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000011158 quantitative evaluation Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 208000032320 Germ cell tumor of testis Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 201000011186 acute T cell leukemia Diseases 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006536 aerobic glycolysis Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 230000014155 detection of activity Effects 0.000 description 2
- 230000014541 detection of hypoxia Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- 210000002468 fat body Anatomy 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000007850 in situ PCR Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000032 mammalian fat body Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000009091 myxoma Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 208000011866 pituitary adenocarcinoma Diseases 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000009443 proangiogenesis Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
- 201000007321 sebaceous carcinoma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000002918 testicular germ cell tumor Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100033714 40S ribosomal protein S6 Human genes 0.000 description 1
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- 101710165425 Alpha-enolase Proteins 0.000 description 1
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101710120075 Beta-1,4-galactosyltransferase 5 Proteins 0.000 description 1
- 102100027386 Beta-1,4-galactosyltransferase 6 Human genes 0.000 description 1
- 101710120070 Beta-1,4-galactosyltransferase 6 Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 101710173353 Cytotoxicity-associated immunodominant antigen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 1
- 101710184673 Enolase 1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 1
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 102000058062 Glucose Transporter Type 3 Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000656896 Homo sapiens 40S ribosomal protein S6 Proteins 0.000 description 1
- 101000611943 Homo sapiens Programmed cell death protein 4 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000002131 PAS domains Human genes 0.000 description 1
- 108050009469 PAS domains Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100040992 Programmed cell death protein 4 Human genes 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006298 SLC2A3 Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000018747 cellular response to hypoxia Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 108010093366 eIF-4B Proteins 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000002246 embryonal cancer Diseases 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010088076 lactate dehydrogenase 2 Proteins 0.000 description 1
- 108010088074 lactate dehydrogenase 3 Proteins 0.000 description 1
- 108010088351 lactate dehydrogenase 4 Proteins 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005776 mitochondrial apoptotic pathway Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 201000001705 nipple carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000019039 oxygen homeostasis Effects 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000012206 semi-quantitative assay Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41510410P | 2010-11-18 | 2010-11-18 | |
| US61/415,104 | 2010-11-18 | ||
| PCT/US2011/061453 WO2012068491A1 (en) | 2010-11-18 | 2011-11-18 | Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013545759A true JP2013545759A (ja) | 2013-12-26 |
| JP2013545759A5 JP2013545759A5 (enExample) | 2015-01-15 |
Family
ID=45217701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540063A Pending JP2013545759A (ja) | 2010-11-18 | 2011-11-18 | 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20120128580A1 (enExample) |
| EP (1) | EP2640372A1 (enExample) |
| JP (1) | JP2013545759A (enExample) |
| WO (1) | WO2012068491A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021162478A1 (ko) * | 2020-02-14 | 2021-08-19 | 사회복지법인 삼성생명공익재단 | 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2023276768A1 (ja) * | 2021-06-29 | 2023-01-05 | 国立大学法人京都大学 | 低酸素バイオマーカー及びその利用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130149392A1 (en) * | 2011-12-12 | 2013-06-13 | Synta Pharmaceuticals Corp. | Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
| US12435377B2 (en) | 2018-11-14 | 2025-10-07 | The Broad Institute, Inc. | Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins |
| CN112618527B (zh) * | 2021-01-20 | 2021-11-09 | 上海交通大学医学院附属第九人民医院 | 一种小分子在制备突变型葡萄膜黑色素瘤药物中的应用 |
| WO2023069727A1 (en) * | 2021-10-21 | 2023-04-27 | Edison Oncology | Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections |
| CN115581775B (zh) * | 2022-09-26 | 2025-09-30 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一种用于治疗骨肉瘤的复合纳米药剂及其制备方法 |
| CN118453879B (zh) * | 2024-05-23 | 2025-10-03 | 大连医科大学附属第二医院 | 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009079338A1 (en) * | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) |
| WO2011133673A1 (en) * | 2010-04-20 | 2011-10-27 | Synta Pharmaceuticals Corp. | Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250255A (en) | 1977-07-11 | 1981-02-10 | Eastman Kodak Company | Assay method for isoenzyme activity |
| US6242208B1 (en) | 1988-07-15 | 2001-06-05 | International Reagents Corporation | LDH1 assay |
| WO2006009940A1 (en) | 2004-06-23 | 2006-01-26 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) salts for treatment of cancers |
| EP1731617A1 (de) | 2005-06-06 | 2006-12-13 | DSM IP Assets B.V. | Rückführung lysierter Biomasse als Nährmedium bei der fermentativen Herstellung von Riboflavin |
| SE530596C2 (sv) | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
| EP2099933A4 (en) | 2006-11-21 | 2010-03-24 | Beth Israel Hospital | HYPOXIA-ASSOCIATED GENES AND PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF PREGNANCY-RELATED COMPLICATIONS |
-
2011
- 2011-11-18 WO PCT/US2011/061453 patent/WO2012068491A1/en not_active Ceased
- 2011-11-18 US US13/300,231 patent/US20120128580A1/en not_active Abandoned
- 2011-11-18 JP JP2013540063A patent/JP2013545759A/ja active Pending
- 2011-11-18 EP EP11793609.6A patent/EP2640372A1/en not_active Withdrawn
-
2013
- 2013-12-27 US US14/141,883 patent/US20140113972A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009079338A1 (en) * | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) |
| WO2011133673A1 (en) * | 2010-04-20 | 2011-10-27 | Synta Pharmaceuticals Corp. | Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers |
Non-Patent Citations (3)
| Title |
|---|
| JPN5014001402; 'ＳＹＮＴＡ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬＳ ＡＮＮＯＵＮＣＥＳ ＵＰＤＡＴＥＤ ＥＬＥＳＣＬＯＭＯＬ ＳＹＭＭＥＴＲＹＳＭ ＤＡＴＡ ＰＲＥＳＥＮＴＥＤ ＡＴ ＭＥＬＡＮＯＭＡ ＸＩＩＩ' ［ＯＮＬＩＮＥ］ , 20091014 * |
| JPN7015002660; Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ， ２０１０， Ｖｏｌ．７０（８ Ｓｕｐｐｌｅｍｅｎｔ）， ｐ．４５４５ * |
| JPN7015002661; Ｓｙｎｔａ Ｐｒｅｓｅｎｔｓ Ｎｅｗ Ｄａｔａ ｏｎ Ｅｌｅｓｃｌｏｍｏｌ （Ｆｏｒｍｅｒｌｙ ＳＴＡ-４７８３） ａｔ ＡＡＣＲ-ＮＣＩ-ＥＯＲＴＣ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｃｏｎｆｅｒｅｎｃｅ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021162478A1 (ko) * | 2020-02-14 | 2021-08-19 | 사회복지법인 삼성생명공익재단 | 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2023276768A1 (ja) * | 2021-06-29 | 2023-01-05 | 国立大学法人京都大学 | 低酸素バイオマーカー及びその利用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2640372A1 (en) | 2013-09-25 |
| WO2012068491A1 (en) | 2012-05-24 |
| US20140113972A1 (en) | 2014-04-24 |
| US20120128580A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140178366A1 (en) | Preselection of subjects for therapeutic treatment based on hypoxic status | |
| Levy et al. | Targeting autophagy in cancer | |
| Pallet et al. | High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria | |
| US20140113972A1 (en) | Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status | |
| US20140024030A1 (en) | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status | |
| US20150253330A1 (en) | Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status | |
| Lamb et al. | Osimertinib: a review in T790M-positive advanced non-small cell lung cancer | |
| JP7399135B2 (ja) | がんにおけるマクロピノサイトーシス | |
| US20230068698A1 (en) | Combination therapy for cancer | |
| WO2012178038A1 (en) | Methods of treating cancer | |
| US20130237546A1 (en) | Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma | |
| JP2022500479A (ja) | Ｃｄｃ７阻害剤を含む癌の治療方法 | |
| KR101242726B1 (ko) | 종양줄기세포 특성 암의 진단 및 치료제 | |
| EP2453234B1 (en) | Methods for prognosing the ability of a zearalenone analog compound to treat cancer | |
| WO2021163072A1 (en) | Method of treating pancreatic cancer | |
| Sung et al. | Ischemia‐induced cardiac dysfunction is exacerbated in adiponectin‐knockout mice due to impaired autophagy flux | |
| Peng et al. | Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth | |
| US20120189544A1 (en) | Gastrointestinal disease or disorder imaging and treatment | |
| EP2407786A1 (en) | Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer | |
| EP2610620A1 (en) | Histone deacetylase 10-inhibitor co-treatment in cancer | |
| Tang et al. | PRC1 mediates downstream PI3K-AKT activation through regulating PTEN ubiquitination degradation in TAC-induced cardiac remodeling | |
| WO2021078937A1 (en) | Treatment of stat3 related diseases by iron chelators | |
| CN111434353A (zh) | Ras抑制剂筛选及疗效标志物 | |
| JP2019094333A (ja) | 心不全の予防または治療用医薬 | |
| Schmidt | The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies Laura S. Schmidt, Ramaprasad Srinivasan, and W. Marston Linehan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20140224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141118 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151221 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160712 |